RESUMO
After years of discussion by the Chilean legislature, the Law Nº 20.584, which regulates health care related rights and duties of people, entered into force in Chile in October 2012. This bill represents an important step in the recognition and protection of health care related rights, welfare, dignity and duties of persons. It also intends to protect potential participants in clinical research. However such protective measures include explicit prohibitions such as the review of clinical records or the inclusion of people with mental or psychological handicaps as research participants. We herein discuss the implications of this law in medical research.
Assuntos
Pesquisa Biomédica/legislação & jurisprudência , Atenção à Saúde/legislação & jurisprudência , Direitos do Paciente/legislação & jurisprudência , Pesquisa Biomédica/ética , Chile , Atenção à Saúde/ética , Humanos , Direitos do Paciente/éticaRESUMO
BACKGROUND AND AIMS: Noncardiac chest pain (NCCP) often represents a diagnostic and therapeutic challenge. Given that gastroesophageal reflux disease (GERD) is the most common cause of NCCP, initial treatment with proton-pump inhibitors (PPI) has been proposed for all patients (PPI testing), reserving esophageal function testing solely for non-responders. The aim of the present study was to provide evidence on the clinical utility of PPI testing with high-dose pantoprazole in patients with NCCP. PATIENTS AND METHODS: We carried out a study of diagnostic performance with a cohort design in patients with NCCP, who had been assessed by the Cardiology Service. All patients underwent upper endoscopy, esophageal manometry, and 24h esophageal pH monitoring before PPI testing with pantoprazole 40 mg every 12h for 1 month. Before and after treatment, we assessed the severity (intensity and frequency) of chest pain, quality of life, and anxiety and depression by means of specific questionnaires. The diagnosis of GERD was based on a pathological finding of esophageal pH monitoring. A positive response to PPI testing was defined as an improvement in chest pain >50% compared with the baseline score after 1 month of PPI therapy. RESULTS: We included 30 consecutive patients (17 men/13 women) with a mean age of 49 years. Of these 30 patients, 20 with NCCP had GERD (67%, 95%CI: 47%-83%). A positive response to PPI therapy was observed in 13 of the 30 (43%) patients with NCCP: 11 of the 20 (55%) patients in the GERD-positive group and 2 of the 10 (20%) in the GERD-negative group. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of PPI testing was 55%, 80%, 85%, 47% and 63%, respectively. A significant reduction in chest pain after pantoprazole therapy (P=.003) and a slight non significant improvement in anxiety and depression was achieved in the GERD-positive group as compared to the GERD-negative group. CONCLUSIONS: In NCCP, PPI testing with pantoprazole has a low sensitivity for the diagnosis of GERD, placing in doubt the strategy of reserving functional study to non-responders to antisecretory therapy. Esophageal function testing and accurate diagnosis would allow appropriate targeted therapy for all patients with NCCP.
Assuntos
2-Piridinilmetilsulfinilbenzimidazóis , Dor no Peito/etiologia , Refluxo Gastroesofágico/complicações , Refluxo Gastroesofágico/diagnóstico , Inibidores da Bomba de Prótons , 2-Piridinilmetilsulfinilbenzimidazóis/uso terapêutico , Estudos de Coortes , Diagnóstico Diferencial , Monitoramento do pH Esofágico , Feminino , Refluxo Gastroesofágico/tratamento farmacológico , Cardiopatias/diagnóstico , Humanos , Masculino , Pessoa de Meia-Idade , Pantoprazol , Inibidores da Bomba de Prótons/uso terapêuticoRESUMO
After years of discussion by the Chilean legislature, the Law Nº 20.584, which regulates health care related rights and duties of people, entered into force in Chile in October 2012. This bill represents an important step in the recognition and protection of health care related rights, welfare, dignity and duties of persons. It also intends to protect potential participants in clinical research. However such protective measures include explicit prohibitions such as the review of clinical records or the inclusion of people with mental or psychological handicaps as research participants. We herein discuss the implications of this law in medical research.
Assuntos
Animais , Masculino , Ratos , Regulação da Expressão Gênica , MicroRNAs/genética , MicroRNAs/metabolismo , Modelos Animais de Doenças , Glomerulonefrite/metabolismo , Hipertensão/patologia , Glomérulos Renais/metabolismo , Túbulos Renais/metabolismo , Rim/lesões , Rim/metabolismo , Ratos Endogâmicos WKY , Fatores de Tempo , Fator de Crescimento Transformador beta/metabolismo , Ureter/patologiaRESUMO
INTRODUCTION AND OBJECTIVES: The aim of this study was to determine the diagnostic value of using myocardial perfusion single-photon emission computed tomography (SPECT) with intravenous atropine administration at the end of submaximal exercise testing. METHODS: One milligram of atropine was administered intravenously at the end of exercise testing to 172 patients who underwent a symptom-limited ergometric test but did not reach 80% of their peak heart rate without exhibiting angina or an ST-segment depression ≥1 mm. Within 1 week, 23 patients who satisfied scintigraphic criteria for ischemia during SPECT with atropine underwent SPECT for a second time without atropine administration with the aim of comparing the presence and severity of scintigraphic ischemia between the two studies (SDS: summed difference score). RESULTS: Of the 172 patients, 75 (43.6%) developed angina (n=56) or ST-segment depression (n=30) during atropine administration. Eight of the 23 patients (35%) who underwent two tests exhibited scintigraphic ischemia (SDS ≥2) on only the test with atropine. Furthermore, the SDS was significantly greater on SPECT imaging with atropine (5.6 ± 4.5 vs. 3.1 ± 2.8; P=.0001). CONCLUSIONS: One-third of patients who met scintigraphic criteria for ischemia at the end of submaximal exercise testing and after atropine administration would not have met those criteria without administration of the drug.
Assuntos
Atropina , Circulação Coronária/fisiologia , Doença das Coronárias/diagnóstico por imagem , Doença das Coronárias/diagnóstico , Teste de Esforço , Coração/diagnóstico por imagem , Antagonistas Muscarínicos , Adulto , Idoso , Idoso de 80 Anos ou mais , Angina Pectoris/diagnóstico , Angina Pectoris/diagnóstico por imagem , Eletrocardiografia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Tomografia Computadorizada de Emissão de Fóton ÚnicoRESUMO
INTRODUCTION AND OBJECTIVES: The aims of this study were to create a Spanish database of normal myocardial perfusion SPECT (single-photon emission computed tomography) data, termed the normal Spanish database, and to compare it with a database of normal data from the North American population. METHODS: We selected 104 healthy volunteers (45 female, mean age 42+/-14 years) who underwent SPECT during stress and at rest. The findings were analyzed using the 4DM-SPECT commercial software package. The resulting normal Spanish database for males and females was compared with the North American population database (from 70 men and 60 women) provided with the 4DM-SPECT software. RESULTS: In the Spanish database, the highest percentage uptake during both stress and rest was observed in medial-lateral region and the lowest, in the basal-septal region. The percentage uptake in the anterior-medial region was significantly lower in women than men, while uptake in the inferior, medial-septal and apical regions was lower in men than women. Data values in the Spanish database were significantly lower for the majority of heart regions than those in the database with the 4DM-SPECT software. CONCLUSIONS: A Spanish database of normal myocardial perfusion SPECT data was created and included separate data for men and women. Significant differences were observed between this database and a commercial North American database that is commonly used in semiquantitative studies.